NASDAQ:ERAS Erasca (ERAS) Stock Forecast, Price & News $1.97 -0.05 (-2.48%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.96▼$2.0550-Day Range$1.97▼$2.9152-Week Range$1.96▼$9.25Volume400,640 shsAverage Volume581,262 shsMarket Capitalization$297.55 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Erasca MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside458.4% Upside$11.00 Price TargetShort InterestBearish9.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector462nd out of 972 stocksPharmaceutical Preparations Industry207th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingErasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Erasca has a forecasted upside of 458.4% from its current price of $1.97.Amount of Analyst CoverageErasca has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.10% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next 3.2 News and Social Media Coverage News SentimentErasca has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Erasca this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows2 people have added Erasca to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders29.80% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.20% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to decrease in the coming year, from ($1.03) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Erasca (NASDAQ:ERAS) StockErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Read More ERAS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERAS Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comErasca to Present at the Cantor Global Healthcare ConferenceSeptember 9, 2023 | finance.yahoo.comErasca, Inc. (ERAS)October 1, 2023 | Behind the Markets (Ad)6.5 Million Americans Are DESPERATE for This New Drug from One Tiny CompanyDecades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>September 5, 2023 | finance.yahoo.comErasca to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 30, 2023 | msn.comErasca doses first patient in solid tumours combo therapy trialAugust 29, 2023 | finance.yahoo.comErasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid TumorsAugust 11, 2023 | finanznachrichten.deErasca, Inc.: Erasca Reports Second Quarter 2023 Financial Results and Business UpdatesAugust 11, 2023 | markets.businessinsider.comErasca (ERAS) Receives a Buy from Mizuho SecuritiesOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 11, 2023 | finance.yahoo.comErasca Reports Second Quarter 2023 Financial Results and Business UpdatesJuly 12, 2023 | msn.comErasca: Trading Near Cash ValueJuly 6, 2023 | msn.comErasca (ERAS) Price Target Decreased by 30.95% to 9.86June 26, 2023 | benzinga.comBoard Member at Erasca Acquires Company Stock Options Worth 60,000 SharesJune 26, 2023 | benzinga.comErasca Board Member Awarded $163K Worth of Stock OptionsJune 22, 2023 | marketwatch.comErasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug DesignationJune 22, 2023 | markets.businessinsider.comErasca's ERAS-801 Gets FDA's Orphan Drug StatusJune 22, 2023 | msn.comFDA grants orphan drug status to Erasca brain cancer drug ERAS-801June 15, 2023 | finance.yahoo.comJonathan Lim Spends US$275k On Erasca StockJune 15, 2023 | finance.yahoo.comJonathan Lim Spends US$275k On Erasca Stock \June 9, 2023 | benzinga.comErasca shares are trading higher after a Form4 filing showed CEO Jonathan Lim acquired 100,000 shares at an average price of $2.75.June 9, 2023 | benzinga.comErasca Insider Trades Send a SignalJune 6, 2023 | msn.comMizuho Maintains Erasca (ERAS) Buy RecommendationJune 6, 2023 | markets.businessinsider.comAnalyst Expectations for Erasca's FutureJune 6, 2023 | finance.yahoo.comErasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity SignalsJune 6, 2023 | markets.businessinsider.comErasca (ERAS) Gets a Buy from Goldman SachsJune 6, 2023 | finanznachrichten.deErasca, Inc.: Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines PipelineJune 5, 2023 | finance.yahoo.comErasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines PipelineSee More Headlines Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Company Calendar Last Earnings8/10/2023Today9/30/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+458.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-242,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.57% Return on Assets-29.04% Debt Debt-to-Equity RatioN/A Current Ratio13.90 Quick Ratio13.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book0.58Miscellaneous Outstanding Shares151,040,000Free Float106,032,000Market Cap$297.55 million OptionableNot Optionable Beta1.10 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jonathan E. Lim M.D. (Age 51)Co-Founder, Chairman & CEO Comp: $940.32kDr. David M. Chacko M.D. (Age 39)CFO & Chief Bus. Officer Comp: $616.76kDr. Michael D. Varney Ph.D. (Age 65)Chairman of R&D, Scientific Advisory Board Member and Director Comp: $83.26kDr. Nik Chetwyn Ph.D.Chief Operating OfficerMr. Ebun S. Garner J.D. (Age 51)Esq., Gen. Counsel & Corp. Sec. Dr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 56)M.S., MS, CPA, Sr. VP of Fin. Ms. Chandra D. Lovejoy M.S. (Age 52)Chief Regulatory Affairs Officer Dr. Robert Shoemaker Ph.D. (Age 42)Sr. VP of Research Dr. Shannon R. Morris M.D. (Age 53)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsNature's Sunshine ProductsNASDAQ:NATRArbutus BiopharmaNASDAQ:ABUSTerns PharmaceuticalsNASDAQ:TERNuniQureNASDAQ:QUREApollomicsNASDAQ:APLMView All CompetitorsInsiders & InstitutionsBarclays PLCSold 17,951 shares on 9/21/2023Ownership: 0.025%Virginia Retirement Systems ET ALBought 24,700 shares on 8/22/2023Ownership: 0.016%California State Teachers Retirement SystemBought 5,811 shares on 8/21/2023Ownership: 0.062%Nuveen Asset Management LLCBought 468,305 shares on 8/16/2023Ownership: 0.781%Citadel Advisors LLCBought 100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ERAS Stock - Frequently Asked Questions Should I buy or sell Erasca stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares. View ERAS analyst ratings or view top-rated stocks. What is Erasca's stock price forecast for 2023? 3 Wall Street analysts have issued 12 month price targets for Erasca's stock. Their ERAS share price forecasts range from $8.00 to $15.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 458.4% from the stock's current price. View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts. How have ERAS shares performed in 2023? Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS stock has decreased by 54.3% and is now trading at $1.97. View the best growth stocks for 2023 here. Are investors shorting Erasca? Erasca saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 8,430,000 shares, a decrease of 5.5% from the August 31st total of 8,920,000 shares. Based on an average daily volume of 508,500 shares, the short-interest ratio is currently 16.6 days. Approximately 9.1% of the company's shares are short sold. View Erasca's Short Interest. When is Erasca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ERAS earnings forecast. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. What ETF holds Erasca's stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 40,125 shares of ERAS stock, representing 0.90% of its portfolio. When did Erasca IPO? (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. What is Erasca's stock symbol? Erasca trades on the NASDAQ under the ticker symbol "ERAS." How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Erasca's stock price today? One share of ERAS stock can currently be purchased for approximately $1.97. How much money does Erasca make? Erasca (NASDAQ:ERAS) has a market capitalization of $297.55 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. How many employees does Erasca have? The company employs 129 workers across the globe. How can I contact Erasca? The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com. This page (NASDAQ:ERAS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.